✦ LIBER ✦

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

✍ Scribed by Ali Taher; Maria D. Cappellini; Elliott Vichinsky; Renzo Galanello; Antonio Piga; Tomasz Lawniczek; Joan Clark; Dany Habr; John B. Porter

Book ID: 108676510
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 121 KB
Volume: 147
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2009.07908.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of deferasirox, an o

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

✍ Ali Taher; Amal El-Beshlawy; Mohsen S. Elalfy; Kusai Al Zir; Shahina Daar; Dany 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB

Deferasirox demonstrates a dose-dependen

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

✍ Taher, Ali T.; Porter, John B.; Viprakasit, Vip; Kattamis, Antonis; Chuncharunee 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

Pharmacokinetics, Metabolism, and Dispos

Pharmacokinetics, Metabolism, and Disposition of Deferasirox in -Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State

✍ Waldmeier, F.; Bruin, G. J.; Glaenzel, U.; Hazell, K.; Sechaud, R.; Warrington, 📂 Article 📅 2010 🏛 American Society for Pharmacology and Experimental 🌐 English ⚖ 734 KB

A safety, pharmacokinetic and pharmacody

A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan

✍ Keisuke Miyazawa; Kazuma Ohyashiki; Akio Urabe; Tomoko Hata; Shinji Nakao; Keiya 📂 Article 📅 2008 🏛 Carden Jennings Publishing 🌐 English ⚖ 378 KB

Long-term safety and efficacy of deferas

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

✍ Elliott Vichinsky; Françoise Bernaudin; Gian Luca Forni; Renee Gardner; Kathryn 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB

Observational study comparing long-term

Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload

✍ Yesim Aydinok; Sule Unal; Yesim Oymak; Canan Vergin; Zeynep D. Türker; Dilek Yil 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB